In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia

Tools

Item Type:	Article
Title:	In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia
Creators Name:	Wang, H., Georgakopoulou, A., Psatha, N., Li, C., Capsali, C., Samal, H.B., Anagnostopoulos, A., Ehrhardt, A., Izsvák, Z., Papayannopoulou, T., Yannaki, E. and Lieber, A.
Abstract:	Current thalassemia gene therapy protocols require the collection of hematopoietic stem/progenitor cells (HSPCs), in vitro culture, lentivirus vector transduction, and retransplantation into myelo-ablated patients. Because of cost and technical complexity, it is unlikely that such protocols will be applicable in developing countries where the greatest demand for a beta-thalassemia therapy lies. We have developed a simple in vivo HSPC gene therapy approach that involved HSPC mobilization and an intravenous injection of integrating HDAd5/35++ vectors. Transduced HSPCs homed back to the bone marrow where they persisted long-term. HDAd5/35++ vectors for in vivo gene therapy of thalassemia had a unique capsid that targeted primitive HSPCs through human CD46, a relatively safe SB100X transposase-based integration machinery, a micro-LCR driven gamma-globin gene and, a MGMT(P140K) system that allowed for increasing the therapeutic effect by short-term treatment with low-dose O(6)BG/BCNU. We showed in "healthy" human CD46 transgenic mice and in a mouse model of thalassemia intermedia that our in vivo approach resulted in stable gamma-globin expression in the majority of circulating red blood cells. The high marking frequency was maintained in secondary recipients. In the thalassemia model, a near complete phenotypic correction was achieved. The treatment was well tolerated. This cost-efficient and "portable" approach could permit a broader clinical application of thalassemia gene therapy.
Keywords:	Adenoviridae, Animal Disease Models, beta-Thalassemia, Cell Line, Erythrocytes, gamma-Globins, Gene Expression Regulation, Genetic Therapy, Genetic Transduction, Genetic Vectors, Hematopoietic Stem Cells, Transgenic Mice, Animals, Mice
Source:	Journal of Clinical Investigation
ISSN:	0021-9738
Publisher:	American Society for Clinical Investigation
Volume:	129
Number:	2
Page Range:	598-615
Date:	1 February 2019
Official Publication:	https://doi.org/10.1172/JCI122836
External Fulltext:	View full text on PubMed Central
PubMed:	View item in PubMed

Repository Staff Only: item control page